Cleveland BioLabs ($CBLI) announces that the company received a response from the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services (BARDA) indicating that BARDA has declined to invite the company to submit a full proposal at this time for continued development funding of CBLB502 as a radiation countermeasure.
Notwithstanding this notification, the company plans to continue the development of CBLI502 as a radiation countermeasure without interruption. Management states..." We will keep pursuing additional funding from various governmental agencies, including BARDA and our existing Department of Defense funding partners at the Chemical Biological Medical Systems and Defense Threat Reduction Agency."
There will be a conference call tomorrow Wednesday April 4, 2012 at 9:00 am 877-643-7158 (US) or 914-495-8565 (International).
